SkinAx²™: grape, melon, vitamin C, zinc and radiance data
In brief. SkinAx²™ is an Activ’Inside combination of a melon concentrate rich in superoxide dismutase, grape-seed extract, vitamin C and zinc. A human study published in 2016 evaluated 150 mg/day for eight weeks in 35 women aged 40 to 70 with a dull complexion. It was open-label, with no placebo: each participant served as her own control. Eclo evidence rating: a published human study on the ingredient at the Eclo dose, but with an open-label design and sponsor/authors linked to the supplier.
SkinAx²™ at a glance
| Type | Nutricosmetic combination of grape, melon, vitamin C and zinc |
|---|---|
| Dose used by Eclo | 150 mg / day |
| Published study | 35 women · age 40–70 · open-label · no placebo · 150 mg/day · 8 weeks |
| Comparator | Each participant compared with her own baseline |
| Funding / affiliations | Study sponsored by Activ’Inside; authors affiliated with Activ’Inside |
| At Eclo | Régénère™ |
Does SkinAx²™ contain collagen?
No. It combines plant ingredients and micronutrients. The supplier’s commercial phrase “vegan collagen booster” does not mean the complex is collagen. Vitamin C has an authorized European claim: it contributes to normal collagen formation for the normal function of skin when the conditions of use are met.
What did the published human study show?
The study published in Clinical, Cosmetic and Investigational Dermatology included 35 women aged 40 to 70 with a dull complexion. They received 150 mg/day for eight weeks. The authors assessed skin colour, luminosity, imperfections, firmness and participants’ perceptions.
Reported findings included a 25.9% increase in luminosity and an overall 18.0% reduction in facial imperfections versus baseline. The authors also reported improvements in certain firmness and elasticity parameters.
Why does the design limit the strength of the conclusion?
The study is open-label and not placebo-controlled. Participants know they are taking the product, and skin can change over time with habits and environment. A before/after difference is therefore less causally convincing than a prespecified difference between a randomized active group and placebo.
The publication also states that the study was sponsored by Activ’Inside, the supplier of SkinAx²™, and that the authors were affiliated with the company. This does not make the results invalid; it increases the value of independent replication and should remain visible when assessing the evidence.
What about the “+34% collagen” figure?
Activ’Inside communicates an in vitro finding on collagen production in a laboratory model. This mechanistic result must not become “+34% collagen in the skin” for people taking Régénère™. A cell-model result and a human clinical outcome are different levels of evidence.
Which claims belong to the micronutrients?
- Vitamin C contributes to normal collagen formation for the normal function of skin and contributes to the protection of cells from oxidative stress, subject to the conditions of use.
- Zinc contributes to the maintenance of normal skin and to the protection of cells from oxidative stress, subject to the conditions of use.
These claims belong to the relevant micronutrients; they are not a clinical trial of SkinAx²™ or Régénère™.
What we know — and what it does not allow us to conclude
- Published study: SkinAx²™ was evaluated at 150 mg/day for eight weeks in 35 women.
- Major limitation: no placebo and no randomized controlled comparison.
- Context: sponsor and authors linked to the supplier.
- Do not extrapolate: in vitro findings are not clinical outcomes.
- Do not extrapolate: this publication is not a study of Régénère™.
Why does Eclo use 150 mg?
150 mg/day matches the dose in the human publication. It is a traceable dose. Reproducing a studied dose improves the match with the ingredient’s evidence dossier, but it does not automatically make a different multi-ingredient formula clinically proven.
Frequently asked questions
Does SkinAx²™ contain collagen?
No. It is a combination of melon, grape, vitamin C and zinc.
Was the SkinAx²™ study randomized against placebo?
No. The 2016 publication describes an open-label study in which each participant served as her own control.
Does +25.9% luminosity mean everyone will gain 25.9%?
No. It is an average change reported in this protocol, not an individual prediction.
Does +34% in vitro mean +34% collagen in the skin?
No. It is a laboratory finding, not a clinical measurement in supplemented people.
Sources
- [Publication] Dumoulin et al., 2016 — human study on SkinAx²™
- [Manufacturer] Activ’Inside — SkinAx²™ and supplier data
- [Regulation] EU Regulation No 432/2012 — authorized claims
Read next
How to read a clinical study · Understanding doses · Skin extracellular matrix · Régénère™
Method note: Eclo makes the study design, funding and limitations visible rather than keeping only favorable numbers.
Last scientific review: 27 August 2026.